References
- Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23: 1234–9
- Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710–21
- Sader HS, Streit JM, Fritsche TR, Jones R. Antimicrobial activity of daptomycin against multi-drug-resistant Gram-positive strains collected worldwide. Diag Micr Inf Dis 2004; 50: 201–4
- Richter SS, Kealey DE, Murray CT, Heilmann KP, Coffman SL. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003; 52: 123–7
- Segreti, J, Crank, CW, Finney, MS. Daptomycin for treatment of drug-resistant Gram-positive bacteremia and infective endocarditis. Abstract 425. In Programs and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America. Boston 2004.
- CLSI/NCCLS. Performance standards for antimicrobial disk susceptibility testing. 15th Informational Supplement. CLSI/NCCLS document M100-S15. WaynePA: CLSI/NCCLS, 2005.
- Moellering RC, Jr. Vancomcyin-resistant enterococci. Clin Infect Dis 1998; 26: 1196–9
- Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clinical Infectious Diseases 2001; 33: 210–9
- Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484–92
- Caron F, Gold HS, Wennersten CB, Farris MG, Moellering RC, Eliiopoulos GM. Influence of erythromycin resistance, inoculum growth phase and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 41: 2749–53
- Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone in the treatment of multi-drug resistant Gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146–51
- Birmingham, MC, Zimmer, GS, Hafkin, B. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant resistant, Gram- positive infections. Abstract 1098. In: Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. San Francisco 1999.
- Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin resistant Enterococcus resistant to linezolid. Lancet 2001; 357: 1179
- Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36: 473–81
- Laganas V, Adler J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphyloccocus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother 2003; 47: 2682–4
- Silverman JA, Oliver N, Andrew T, Tongchuan L. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45: 1799–1802
- Woodford N. Novel agents for treatment of resistant Gram-positive infections. Expert Opinion Investigation Drugs 2003; 12: 117–37
- Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004; 38: 994–1000
- Arbeit RD, Maki D, Tally FP, Campanaro E, Eisentein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673–81
- Toro, PL, Kubin, CJ, Della-Latta, P, Pancholi, P, Hammer, S. Linezolid and vancomycin resistant Enterococcus faecium (VREF) bacteremia in a liver transplant patient treated with daptomycin after developing quinupristin-dalfopristin resistance. Abstract K-870. In: Programs and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. Washington, DC 2004.